Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A. Blicklé JF, et al. Among authors: shestakova m. Diabetes Obes Metab. 2009 Apr;11(4):379-86. doi: 10.1111/j.1463-1326.2008.00980.x. Epub 2008 Dec 14. Diabetes Obes Metab. 2009. PMID: 19087105 Clinical Trial.
Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM; PRESENT Study Group. Khutsoane D, et al. Among authors: shestakova m. Diabetes Obes Metab. 2008 Mar;10(3):212-22. doi: 10.1111/j.1463-1326.2007.00826.x. Diabetes Obes Metab. 2008. PMID: 18269636 Clinical Trial.
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group. Porta M, et al. Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12. Diabetologia. 2011. PMID: 21225239 Free article. Clinical Trial.
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators. Meneghini L, et al. Among authors: shestakova m. Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22. Diabetes Care. 2013. PMID: 23340894 Free PMC article. Clinical Trial.
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, Cid-Ruzafa J, Charbonnel B, Fenici P, Hammar N, Hashigami K, Kosiborod M, Nicolucci A, Shestakova MV, Ji L, Pocock S. Khunti K, et al. Among authors: shestakova mv. Diabetes Obes Metab. 2018 Feb;20(2):389-399. doi: 10.1111/dom.13083. Epub 2017 Sep 28. Diabetes Obes Metab. 2018. PMID: 28817227 Free PMC article.
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S. Nicolucci A, et al. Among authors: shestakova mv. Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5. Diabetes Obes Metab. 2019. PMID: 31297947 Free PMC article.
Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators. Khunti K, et al. Among authors: shestakova mv. Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1. Diabetes Obes Metab. 2020. PMID: 31468637 Free PMC article.
Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
Khunti K, Charbonnel B, Cooper A, Gomes MB, Ji L, Leigh P, Nicolucci A, Rathmann W, Shestakova MV, Siddiqui A, Tang F, Watada H, Chen H; DISCOVER investigators. Khunti K, et al. Diabetes Obes Metab. 2021 Aug;23(8):1823-1833. doi: 10.1111/dom.14400. Epub 2021 May 3. Diabetes Obes Metab. 2021. PMID: 33852202
268 results